CNBC Africa·2 min read·medium
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
R
Reuters
✦AI Summary
Researchers in the Democratic Republic of Congo have launched a clinical trial for Gilead Sciences' experimental antiviral drug, obeldesivir, to treat the Bundibugyo Ebola outbreak. The study is supported by international medical organizations in the Ituri province.
July 14 (Reuters) – Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences’ GILD.O experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.
healthsciencebusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in